pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ninlaro
drug · small molecule
save

ixazomib citrate

Marketedupdated 3mo ago
by Millennium Pharmaceuticals Inc🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and amyloidosis and 7 investigational indications.

targets

26S proteasome

all catalysts(0)

nothing on the calendar yet

Trials studying ixazomib citrate

  • phase2Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphomaactive not recruitingn=33
  • phase1SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosisrecruitingn=72
  • phase2Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapyterminatedn=15
  • phase3A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplantcompletedn=656
  • phase2Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myelomaactive not recruitingn=30

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 6, 2027
353 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (21)

  • Nov 20, 2029compositionUS 74428303.3y
  • Nov 20, 2029compositionUS 74428303.3y
  • Nov 20, 2029compositionUS 74428303.3y
  • Jun 16, 2029compositionUS 88595042.8y
  • Jun 16, 2029compositionUS 88595042.8y
  • Jun 16, 2029compositionUS 88595042.8y
  • Jun 16, 2029method-of-use (U-2434)US 91750172.8y
  • Jun 16, 2029method-of-use (U-2434)US 91750172.8y
  • Jun 16, 2029method-of-use (U-2434)US 91750172.8y
  • Aug 6, 2027compositionUS 7687662353d
  • Aug 6, 2027compositionUS 7687662353d
  • Aug 6, 2027compositionUS 7687662353d
  • Aug 6, 2027compositionUS 8003819353d
  • Aug 6, 2027compositionUS 8003819353d
  • Aug 6, 2027compositionUS 8003819353d
  • Aug 6, 2027compositionUS 8530694353d
  • Aug 6, 2027compositionUS 8530694353d
  • Aug 6, 2027compositionUS 8530694353d
  • Aug 6, 2027method-of-use (U-2434)US 8871745353d
  • Aug 6, 2027method-of-use (U-2434)US 8871745353d
  • Aug 6, 2027method-of-use (U-2434)US 8871745353d

News(0)

no news has mentioned this drug yet

brand
Ninlaro
trade names
Ninlaro
generic
ixazomib citrate
MOA
26S proteasome inhibitor
indication
Refractory Multiple Myeloma
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?